Ketamine Clinic Marketing Compliance Guide: IV Ketamine for Depression Without Triggering an FDA Letter
Most ketamine clinic marketing problems are not exotic - they are six or seven repeated phrases that the FDA October 2023 communication and 2024 enforcement actions have already singled out. This guide focuses on the IV ketamine for depression use case and rewrites the patterns that get clinics in trouble.
Ketamine clinic marketing for depression sits in a narrow, well-mapped regulatory corridor. The FDA issued an October 2023 public communication specifically about compounded ketamine products marketed for psychiatric disorders. The FTC has separate substantiation rules for outcome and testimonial language. State medical boards and the DEA are watching prescribing behavior. The good news: the patterns regulators care about are repetitive, and you can rewrite around them without losing the marketing message.
This guide focuses tightly on the IV racemic-ketamine for depression use case - the dominant ketamine clinic offering - and walks through five compliance pitfalls and the rewrites that work in 2026. It is the practical companion to our broader ketamine clinic marketing compliance overview and is meant to be read with your live website open in another tab.
Pitfall 1: Conflating racemic ketamine with Spravato
Spravato (esketamine), the intranasal product from Janssen, is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, under a Risk Evaluation and Mitigation Strategy (REMS) program. Racemic ketamine, the molecule used in most IV ketamine clinics, is FDA-approved as an anesthetic - not as a psychiatric therapy. They are not the same product, not the same legal status, and not the same risk profile.
“We offer the same proven depression treatment that the FDA approved in 2019 - delivered in a more comfortable IV format.”
“Esketamine (Spravato) is FDA-approved for certain forms of depression under a REMS program; the IV ketamine our clinic provides is an off-label use of an FDA-approved anesthetic, prescribed at the clinician's discretion and not subject to the same FDA approval or REMS.”
Why: The bad version implies the IV product carries the FDA approval that actually belongs to a different, intranasal, manufactured drug. That is the equivalence pattern called out in the FDA October 2023 communication.
Pitfall 2: Disease cure and outcome guarantee language
Depression, PTSD, anxiety, and chronic pain are diagnosable medical conditions. Claiming to cure, treat, or reverse them with ketamine triggers FDA disease-claim rules on top of FTC substantiation requirements. The phrase treatment-resistant depression is particularly sharp because it is the labeled indication for Spravato but not for racemic ketamine.
“Cure your treatment-resistant depression in 6 sessions - guaranteed results or your money back.”
“Some patients with depression that has not responded to first-line therapies report meaningful symptom relief during a course of IV ketamine. Response rates and durability vary; our clinical team will discuss the published literature and the limits of the evidence during your consultation.”
Why: The bad version cures a labeled diagnosis (disease claim), uses a Spravato-coded indication phrase, and adds a money-back outcome guarantee. The compliant version describes the same offer using subjective-report language and acknowledges variability.
Pitfall 3: Safety overstatement
Ketamine has a defined adverse-event profile: dissociation, elevated blood pressure, nausea, lower-urinary-tract effects at long-term high dose, and abuse-liability concerns appropriate to a Schedule III controlled substance. Marketing that calls IV ketamine safe, side-effect-free, or non-addictive is contradicted by the labeling and by clinical literature, and is a pattern the FDA specifically flagged.
“Ketamine therapy is safe, non-addictive, and has no significant side effects.”
“Ketamine is a Schedule III controlled substance with a known side-effect profile that includes transient dissociation, increases in blood pressure and heart rate, nausea, and abuse potential. Our protocols include monitoring during and after each infusion.”
Why: The safe-and-side-effect-free framing is one of the recurring patterns in FDA and state-board action against compounded-ketamine marketing. Honest risk disclosure also builds trust with the patient population you want.
Pitfall 4: At-home and unsupervised-use framing
The FDA October 2023 communication was, in part, a response to the rapid growth of mailed and at-home compounded ketamine offerings that the agency considered to pose unacceptable patient risk. If your clinic ships compounded oral or sublingual ketamine for unsupervised home use, the marketing cannot present that as a casual or low-friction service.
“Get prescription ketamine delivered to your door - take it whenever you need a reset.”
“At-home oral ketamine is provided only after in-clinic clinical evaluation, by patient-specific prescription where the prescriber has determined supervised in-clinic delivery is not required for this patient. Compounded ketamine is not FDA-approved for any psychiatric indication.”
Why: A whenever-you-need-a-reset frame is consumer-product language for a Schedule III controlled substance, and reads exactly like the marketing the FDA called out as creating patient risk.
Pitfall 5: Transformational testimonial copy
Patient testimonials in mental-health marketing are subject to the FTC Endorsement Guides, including the 2023 update that tightened material-connection and typical-experience disclosure requirements. Dramatic single-patient outcomes presented as representative outcomes - without typical-experience disclosure and without substantiation - are the exact pattern the FTC has actioned in adjacent depression-related marketing.
“I had failed every antidepressant for 15 years. After 3 ketamine sessions I am finally free. (typical patient story)”
“One patient described meaningful improvement in mood and function after a course of IV ketamine; clinical response rates in published racemic-ketamine literature vary and many patients do not experience this degree of change. Individual outcomes are not predictive of yours.”
Why: The bad version uses a single dramatic outcome as a typical-experience claim. The FTC Endorsement Guides require either typical-experience evidence or clear disclosure that the result is atypical.
Do and don’t at a glance
- Do distinguish FDA-approved Spravato from off-label racemic-ketamine in plain language.
- Do disclose the controlled-substance status, the side-effect profile, and the off-label nature of the use.
- Do frame patient outcomes as variable and individual, with typical-experience disclosure on testimonials.
- Don’t use the labeled Spravato indication phrase treatment-resistant depression to describe what your IV ketamine program treats.
- Don’t use safe, no-side-effects, or non-addictive language for a Schedule III controlled substance.
- Don’t market at-home or unsupervised ketamine as a low-friction wellness product.
Adjacent reading
Ketamine clinics frequently operate alongside IV nutrient and NAD+ programs. The marketing-language patterns are different but the substantiation framework is shared. See our note on the FDA position around NAD+ IV therapy marketing for the parallel.
Built for this exact problem
Scan your clinic's content before regulators do.
RegenCompliance checks every word of your marketing against live FDA and FTC enforcement data - and rewrites violations automatically. A 30-second scan can save a $50,000–$5M regulatory response.
Related in the platform
Weekly compliance brief
One email a week. New enforcement actions, rule changes, and tactical fixes. No spam, unsubscribe anytime.
Keep reading
Compounded GLP-1 Marketing Compliance in 2026: What Changed When the Shortage List Closed
When the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis for routine 503A compounding narrowed. Your existing compounded-GLP-1 marketing was probably written for the old posture. Here is the 2026 rewrite.
Read articleNAD+ IV Therapy Marketing and the FDA Position: What Actually Has Approval, What Does Not, and How to Word It
Most NAD+ IV therapy marketing trouble is upstream of the FTC longevity-claim issue. It is the quiet implication that NAD+ has some kind of FDA status it does not have. Here is the actual FDA position and how to word a NAD+ program page around it.
Read articleOzone Therapy Marketing Compliance Rules: The FDA Position on Medical Ozone and the Phrases That Trigger Action
The FDA has stated publicly that ozone is a toxic gas with no known useful medical application. That position is the entire frame for ozone therapy marketing. Most ozone clinic copy is written as if the FDA is silent on the topic - it is not.
Read article